# OnCo record sotio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/sotio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "sotio" ;
  schema:name "SOTIO Biotech"@en ;
  schema:alternateName "SOTIO a.s."@en, "SOTIO"@en ;
  schema:description "SOTIO is a Prague biotechnology company owned by the PPF group whose dendritic cell vaccine for prostate cancer failed its phase 3 trial in 2020, and which now develops an IL-15 superagonist and antibody-drug conjugates."@en ;
  schema:url <https://onco.cc/companies/sotio/>, <https://www.sotio.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.sotio.com>, <https://clinicaltrials.gov/search?lead=SOTIO> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "CZ" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/adcs/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:trials <https://onco.cc/trials/nct05120271/> .